| Authors: |
Chen HX; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), Bethesda, Maryland. thurinm@mail.nih.gov helen.chen@nih.gov., Song M; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), Bethesda, Maryland., Maecker HT; The Human Immune Monitoring Center (HIMC), Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, California., Gnjatic S; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Patton D; Center for Biomedical Informatics and Information Technology, NCI, Bethesda, Maryland., Lee JJ; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas., Adam SJ; Foundation for the National Institutes of Health, North Bethesda, Maryland., Moravec R; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland.; Kelly Services, Rockville, Maryland., Liu XS; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Cerami E; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Lindsay J; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Tang M; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Hodi FS; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Wu CJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts.; Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Wistuba II; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Al-Atrash G; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bernatchez C; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Bendall SC; Department of Pathology, School of Medicine, Stanford University, Stanford, California., Hewitt SM; Laboratory of Pathology, Center for Cancer Research, NCI, Bethesda, Maryland., Sharon E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), Bethesda, Maryland., Streicher H; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), Bethesda, Maryland., Enos RA; The Emmes Company, LLC, Rockville, Maryland., Bowman MD; The Emmes Company, LLC, Rockville, Maryland., Tatard-Leitman VM; The Emmes Company, LLC, Rockville, Maryland., Sanchez-Espiridion B; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas., Ranasinghe S; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., Pichavant M; The Human Immune Monitoring Center (HIMC), Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, California., Del Valle DM; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Yu J; Department of Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts., Janssens S; The Emmes Company, LLC, Rockville, Maryland., Peterson-Klaus J; Foundation for the National Institutes of Health, North Bethesda, Maryland., Rowe C; Center for Biomedical Informatics and Information Technology, NCI, Bethesda, Maryland.; Essex Management, Rockville, Maryland., Bongers G; Microbiome Translational Center, Precision Immunology Institute, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York., Jenq RR; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Chang CC; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas., Abrams JS; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), Bethesda, Maryland., Mooney M; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI), Bethesda, Maryland., Doroshow JH; Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Harris LN; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland., Thurin M; Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland. thurinm@mail.nih.gov helen.chen@nih.gov. |
